David Hodgson

Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Adolescents With Gevorderd-Stage Classic Hodg...

Subsequent Neoplasm Risico After Modern Mediastinal Radiotherapie for Pediatric Hodgkin Lymphoma: Insights From a Multi-Institutional Children’s Oncology Group Trial

Enhancing Radiotherapie Quality Assurance in Lymphoma: A Rigorous Real-Time Central Review Process in AHOD2131

Multimodality Artificial Intelligence for Involved-Site Radiotherapie: Clinical Target Volume Delineation in High-Risico Pediatric Hodgkin Lymphoma

Impact of immunochemotherapy regimens on outcomes of patiënten met primary mediastinal B-cell lymphoma in the IELSG37...

Group-based trajectories of health-related quality of life among pediatric patiënten met high-risk Hodgkin lymphoma.

Weglating van RT bij primair mediastinaal B-cellymfoom: IELSG37 fase III

Nivolumab plus AVD bij gevorderd klassiek hodgkinlymfoom: SWOG S1826 fase III

BV plus chemotherapie bij pediatrisch hoogrisico hodgkinlymfoom: AHOD1331 fase III

Overleving naar leeftijd bij pediatrisch hodgkinlymfoom: retrospectieve gepoolde analyse

Lage-dosis tamoxifen bij bestraalde kankeroverlevenden met verhoogd borstkankerrisico: fase IIb